Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle

Study of MVI-118 Prostate Cancer Vaccine Expands, Adding Site in Seattle
A Phase 1 study evaluating the MVI-118 cancer vaccine in patients with metastatic prostate cancer is expanding to a third clinical site, the University of Washington in Seattle. The trial is studying whether MVI-118 can be used in combination with androgen deprivation therapy (ADT) to delay treatment resistance and prolong disease control in patients whose prostate cancer has spread to other areas of the body. It is already going in two clinical sites, the University of Wisconsin-Madison and the Rutgers Cancer Institute in New Jersey. "Many patients are reluctant to start chemotherapy treatment, especially if they are feeling well,” Michael Schweizer, MD, principal investigator at the University of Washington School of Medicine, said in a press release. “This study will provide vital information about the safety as well as the clinical and immunologic effects of a novel approach to treatment that may move us toward an effective alternative to chemotherapy for these men." MVI-118 is a plasmid DNA, or circular molecule of DNA, that contains the genetic information of the androgen receptor (AR). It is designed to foster constant activation of CD8-positive T-cells to induce potent immune responses against AR-positive cancer cells. This type of cancer vaccine can be manufactured rapidly, and is more stable in storage than a lot of other vaccines. In addition, the vaccine doesn't need to be individually engineered for each patient. “Although commonly referred to as ‘vaccines,’ our products are actually forms o
Subscribe or to access all post and page content.